New website
coming soon
Curileum is developing novel therapies that restore the health of gastrointestinal tissues, intervening early in disease development to prevent bowel cancer and treat inflammatory bowel disease. The company is backed by over 40 years of drug discovery, targeting diseases in the body’s two most regenerative tissues: the bone marrow and the single layer of the intestinal mucosa.
Its team has raised over $20m to advance novel GI therapies through to late-stage preclinical development.
Novel oral small molecule
Curileum discovered and is developing ULI-262, an oral small molecule that addresses the root cause of bowel cancer: abnormal cell production driving polyp formation. By re-directing precancerous cells back toward normal tissue, ULI-262 may prevent progression to cancer — offering the first scalable, non-invasive pharmacological solution.
Fundraising
We are currently fundraising to progress ULI262 into stage 1 clinical trials – please contact info@curileum.com for further information.
ATZ stem cells
The Curileum team has identified a new source of multipotent adult stem cells, ATZ, found in the lower part of the gut. ATZ stem cells could offer the first curative treatment for perianal fistulas in Crohn’s patients.
Dr Jeff Moore, Founder and CEO
Dr Jeff Moore has worked at the forefront of research into the regulation of cell production throughout his career. He previously led the discovery and development of a novel protein that protected the bone marrow and GI tract from the toxicity of chemotherapy.
Get in touch: info@curileum.com